US 7361752
RNAi modulation of MLL-AF4 and uses thereof
granted A61PA61P35/00A61P35/02
Quick answer
US patent 7361752 (RNAi modulation of MLL-AF4 and uses thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Apr 17 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Apr 22 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 17 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 7
- CPC classes
- A61P, A61P35/00, A61P35/02, A61P43/00